Maximum Tolerated Dose
Showing 1 - 25 of >10,000
Amyotrophic Lateral Sclerosis Trial in Hualien City (HK-001, Placebo control)
Active, not recruiting
- Amyotrophic Lateral Sclerosis
- HK-001
- Placebo control
-
Hualien City, TaiwanHualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation
Jan 16, 2023
Relapsed/Refractory Diffuse Large B-cell Lymphoma and Multiples Myeloma Trial in Dresden (MDC-CAR-BCMA001 (BCMA directed CAR
Not yet recruiting
- Relapsed/Refractory Diffuse Large B-cell Lymphoma and Multiples Myeloma
- MDC-CAR-BCMA001 (BCMA directed CAR T-cells)
-
Dresden, GermanyTechnische Universität Dresden, NCT/UCC, Early Clinical Trial Un
Apr 19, 2023
Advanced Solid Tumors Trial in Huntersville, Cleveland (2X-121 and dovitinib)
Recruiting
- Advanced Solid Tumors
- 2X-121 and dovitinib
-
Huntersville, North Carolina
- +1 more
Feb 1, 2023
Basal Cell Carcinoma Trial in Aventura (Placebo-containing MNA, 25 µg doxorubicin-containing MNA, 50 µg doxorubicin-containing
Terminated
- Basal Cell Carcinoma
- Placebo-containing MNA
- +4 more
-
Aventura, FloridaThe Center for Clinical and Cosmetic Research
Aug 16, 2022
Colon Cancer Stage I Trial in Taoyuan (Magicell-NK contains NK cells suspended in 100 mL normal saline)
Recruiting
- Colon Cancer Stage I
- Magicell-NK contains NK cells suspended in 100 mL normal saline
-
Taoyuan, TaiwanChang Gung Memorial Hospital, Linkou
Sep 28, 2022
Glioblastoma Multiforme Trial in Seoul (BEY1107, Temozolomide)
Recruiting
- Glioblastoma Multiforme
- BEY1107
- Temozolomide
-
Seoul, Korea, Republic ofSeoul National University Hospital
Mar 13, 2023
Malignant Solid Tumour Trial in Santa Monica (INNO-206)
Completed
- Malignant Solid Tumour
-
Santa Monica, CaliforniaSarcoma Oncology Center
Jan 27, 2022
Advanced Solid Tumor Trial in Santa Monica (aldoxorubicin)
Completed
- Advanced Solid Tumor
-
Santa Monica, CaliforniaSarcoma Oncology Center
Jan 27, 2022
Hodgkin's Lymphoma, Lymphoma, Non-Hodgkin Trial in Ann Arbor (Bortezomib, Ruxolitinib)
Completed
- Hodgkin's Lymphoma
- Lymphoma, Non-Hodgkin
-
Ann Arbor, MichiganUniversity of Michgan Comprehensive Cancer Center
Dec 3, 2021
MuSK Myasthenia Gravis Trial (MuSK-CAART)
Not yet recruiting
- MuSK Myasthenia Gravis
- MuSK-CAART
- (no location specified)
Jul 5, 2022
Multiple Myeloma Trial (BCMA-TGFß CAR-T cells (0.75 x10^6 cells/kg), BCMA-TGFß CAR-T cells (1 x 10^6 cells/kg), BCMA-TGFß CAR-T
Not yet recruiting
- Multiple Myeloma
- BCMA-TGFβ CAR-T cells (0.75 x10^6 cells/kg)
- +3 more
- (no location specified)
Jul 28, 2023
Glioblastoma, Adult Gliosarcoma, Tumors, Brain Trial in Seongnam (MSC11FCD)
Enrolling by invitation
- Glioblastoma
- +4 more
-
Seongnam, Kyunggido, Korea, Republic ofBundang CHA Medical Center
Jan 6, 2022
Glioma Trial in Dallas, Houston, San Antonio (Rhenium Liposome Treatment)
Recruiting
- Glioma
- Rhenium Liposome Treatment
-
Dallas, Texas
- +2 more
Nov 3, 2021
Healthy Volunteer Trial in Manchester (WP1122, Placebo)
Recruiting
- Healthy Volunteer
- WP1122
- Placebo
-
Manchester, United KingdomMedicines Evaluation Unit
May 12, 2022
Opiate Withdrawal Syndrome Trial in Manchester, London (DMX-1002, Placebo)
Recruiting
- Opiate Withdrawal Syndrome
- DMX-1002
- Placebo
-
Manchester, Greater Mancherster, United Kingdom
- +1 more
Jul 29, 2022
Breast Cancer, Gastric Cancer, Gastroesophageal-junction Cancer Trial in Australia (IKS014)
Not yet recruiting
- Breast Cancer
- +2 more
-
Concord, New South Wales, Australia
- +4 more
May 30, 2023
Recurrent Bladder Carcinoma, Bladder Cancer Stage 0, Bladder Cancer Stage I Trial in Los Angeles (Pharmacokinetic Study,
Not yet recruiting
- Recurrent Bladder Carcinoma
- +2 more
- Pharmacokinetic Study
- Recombinant EphB4-HSA Fusion Protein
-
Los Angeles, CaliforniaUSC / Norris Comprehensive Cancer Center
Jan 31, 2023
Pancreas Adenocarcinoma Trial in Detroit, Milwaukee (CPI-613® (Dose level -1.0 250 mg/m^2), CPI-613® (Dose level 1.0 500
Recruiting
- Pancreas Adenocarcinoma
- CPI-613® (Dose level -1.0 250 mg/m^2)
- +6 more
-
Detroit, Michigan
- +1 more
Nov 9, 2022
Chemo-refractory Colorectal Carcinoma Trial in Hamburg, Ulm (Maximum tolerated dose, MTD: D,L-methadone HCl (Methasan® 10
Recruiting
- Chemo-refractory Colorectal Carcinoma
- Maximum tolerated dose, MTD: D,L-methadone hydrochloride (Methasan® 10 mg/ml)
-
Hamburg, Germany
- +1 more
Apr 21, 2022